Protective effects of cholecystokinin-8 on methamphetamine-induced behavioral changes and dopaminergic neurodegeneration in mice

Behavioural Brain Research

Volumn 283, Issue , 2015, Pages 87-96

  Gou, Hongyan ^a   Wen, Di ^a   Ma, Chunling ^a   Li, Ming ^a   Li, Yingmin ^a   Zhang, Wenfang ^b   Liu, Li ^b   Cong, Bin ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Beijing Municipal Public Security Bureau   (China)

Author keywords

CCK 8; Methamphetamine; Neurodegeneration; Sensitization; Stereotypic behavior

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE; CHOLECYSTOKININ; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; HYPERACTIVITY; HYPERTHERMIA; MALE; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; RECTUM TEMPERATURE; STEREOTYPY; SUBSTANTIA NIGRA; ANIMAL; BODY TEMPERATURE; C57BL MOUSE; CHEMICALLY INDUCED; DOPAMINERGIC NERVE CELL; DRUG ABUSE; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; METABOLISM; MOTOR ACTIVITY; NEURODEGENERATIVE DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; BODY TEMPERATURE; CHOLECYSTOKININ; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; MALE; METHAMPHETAMINE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RANDOM ALLOCATION; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84922426587     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.01.028     Document Type: Article

References (59)

1. Yamamoto B.K., Moszczynska A., Gudelsky G.A. Amphetamine toxicities: classical and emerging mechanisms. Ann NY Acad Sci 2010, 1187:101-121.
2. Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of drugs of abuse-the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues Clin Neurosci 2009, 11:305-317.
3. Itzhak Y., Martin J.L., Ali S.F. Methamphetamine-induced dopaminergic neurotoxicity in mice: long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:1177-1183.
4. Hall Darien A., Stanis Jessica J., Avila Hector M., Gulley Joshua M. A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior. Psychopharmacology (Berl) 2008, 195:469-478.
5. Ujike H., Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann NY Acad Sci 2004, 1025:279-287.
6. Rebec G.V., Bashore T.R. Critical issues in assessing the behavioral effects of amphetamine. Neurosci Biobehav Rev 1984, 8:153-159.
7. Wood Suzanne, Sage Jennifer R., Shuman Tristan, Anagnostaras Stephan G. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacol Rev 2013, 66:193-221.
8. Pritchard L.M., Hensleigh E., Lynch S. Altered locomotor and stereotyped responses to acute methamphetamine in adolescent, maternally separated rats. Psychopharmacology 2012, 223:27-35.
9. Xi Z.-X., Kleitz H.K., Deng X., Ladenheim B., Peng X.-Q., Li X., et al. A single high dose of methamphetamine increases cocaine self-administration by depletion of striatal dopamine in rats. Neuroscience 2009, 161(2):392-402.
10. Balsara J.J., Jadhav J.H., Muley M.P., Chandorkar A.G. Effect of drugs influencing central serotonergic mechanisms on methamphetamine-induced stereotyped behavior in the rat. Psychopharmacology (Berl) 1979, 64:303-307.
11. Matsumoto R.R., Seminerio M.J., Turner R.C., Robson M.J., Nguyen L., Miller D.B., et al. Methamphetamine-induced toxicity: an updated review on issues related to hyperthermia. Pharmacol Ther 2014, 144:28-40.
12. Mutt V., Jorpes J.E. Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin. Eur J Biochem 1968, 6:156-162.
13. Noble F., Roques B.P. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol 1999, 58:349-379.
14. Bohme G.A., Blanchard J.C. Cholecystokinins and their receptors, functional aspects. Therapie 1992, 47:541-548.
15. Rehfeld J.F., Holst J.J., Jensen S.L. The molecular nature of vascularly released cholecystokinin from the isolated perfused porcine duodenum. Regul Pept 1982, 3:15-28.
16. Wen D., Sun D., Zang G., Hao L., Liu X., Yu F., et al. Cholecystokinin octapeptide induces endogenous opioid-dependent anxiolytic effects in morphine-withdrawal rats. Neuroscience 2014, 277c:14-25.
17. Yang S., Wen D., Dong M., Li D., Sun D., Ma C., et al. Effects of cholecystokinin-8 on morphine-induced spatial reference memory impairment in mice. Behav Brain Res 2013, 256:346-353.
18. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides 1994, 15:731-755.
19. Huston J.P., Schildein S., Gerhardt P., Privou C., Fink H., Hasenöhrl R.U. Modulation of memory, reinforcement and anxiety parameters by intra-amygdala injection of cholecystokinin-fragments Boc-CCK-4 and CCK-8s. Peptides 1998, 29.
20. Voits M., Hasenöhrl R.U., Huston J.P., Fink H. Repeated treatment with cholecystokinin octapeptide improves maze performance in aged Fischer 344 rats. Peptides 2001, 22.
21. Zippel U., Plagemann A., Davidowa H. Altered action of dopamine and cholecystokinin on lateral hypothalamic neurons in rats raised under different feeding conditions. Behav Brain Res 2003, 147:89-94.
22. Helm K.A., Rada P., Hoebel B.G. Cholecystokinin combined with serotonin in the hypothalamus limits accumbens dopamine release while increasing acetylcholine: a possible satiation mechanism. Brain Res 2003, 963:290-297.
23. Martin T.A., Jayanthi S., McCoy M.T., Brannock C., Ladenheim B., Garrett T., et al. Methamphetamine causes differential alterations in gene expression and patterns of histone acetylation/hypoacetylation in the rat nucleus accumbens. PLoS ONE 2012, 7:e34236.
24. Loonam T.M., Noailles P.A., Yu J., Zhu J.P., Angulo J.A. Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum. Life Sci 2003, 73.
25. Vaccarino F.J., Rankin J. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function. Behav Neurosci 1989, 103:831-836.
26. Li S., Ni Z., Cong B., Gao W., Xu S., Wang C., et al. CCK-8 inhibits LPS-induced IL-1beta production in pulmonary interstitial macrophages by modulating PKA, p38, and NF-kappaB pathway. Shock 2007, 27:678-686.
27. Li Q., Cong B., Shan B., Zhang J., Chen H., Wang T., et al. Cholecystokinin octapeptide exerts its therapeutic effects on collagen-induced arthritis by suppressing both inflammatory and Th17 responses. Rheumatol Int 2011, 31:1291-1298.
28. He Z., Yan L., Yong Z., Dong Z., Dong H., Gong Z. Chicago sky blue 6B, a vesicular glutamate transporters inhibitor, attenuates methamphetamine-induced hyperactivity and behavioral sensitization in mice. Behav Brain Res 2013, 239:172-176.
29. Ren Q., Zhang J.-C., Ma M., Fujita Y., Wu J., Hashimoto K. 7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology 2013, 231:159-166.
30. Koros E., Rosenbrock H., Birk G., Weiss C., Sams-Dodd F. The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats. Neuropsychopharmacology 2007, 32:562-576.
31. Jung B.D., Shin E.-J., Nguyen X.-K., Jin C.-H., Bach J.-H., Park S.J., et al. Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem Int 2010, 56:229-244.
32. Boger H.A., Middaugh L.D., Granholm A.-C., McGinty J.F. Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice. Neurobiol Dis 2009, 33:459-466.
33. Kawasaki T., Ishihara K., Ago Y., Nakamura S., Itoh S., Baba A., et al. Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Eur J Pharmacol 2006, 542:92-99.
34. Wen D., Cong B., Ma C., Yang S., Yu H., Ni Z., et al. The effects of exogenous CCK-8 on the acquisition and expression of morphine-induced CPP. Neurosci Lett 2012, 510:24-28.
35. Hirosue Y., Inui A., Miura M., Nakajima M., Okita M., Himori N., et al. Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice. Peptides 1992, 13:155-157.
36. Wen D., Zang G., Sun D., Yang S., Yu F., Li S., et al. Effects of CCK-8 on the reinstatement of morphine-induced CPP and expression of behavioral sensitization in rats. Neuroscience 2013, 238:230-241.
37. Bjorklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007, 30:194-202.
38. Takeda Y., Kamiya Y., Honda K., Takano Y., Kamiya H. Effect of injection of CCK-8 into the nucleus caudatus on the behavior of rats. Jpn J Pharmacol 1986, 40:569-575.
39. Hurd Y.L., Lindefors N., Brodin E., Brene S., Persson H., Ungerstedt U., et al. Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission. Brain Res 1992, 578:317-326.
40. Crawley J.N. Cholecystokinin potentiates dopamine-mediated behaviors in the nucleus accumbens, a site of CCK-DA co-existence. Psychopharmacol Bull 1985, 21:523-527.
41. Seroogy K.B., Dangaran K., Lim S., Haycock J.W., Fallon J.H. Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions. J Comp Neurol 1989, 279:397-414.
42. Záborszky L., Alheid G.F., Beinfeld M.C., Eiden L.E., Heimer L., Palkovits M. Cholecystokinin innervation of the ventral striatum: a morphological and radioimmunological study. Neuroscience 1985, 14:427-453.
43. Vanderhaeghen J.J., Lotstra F., De Mey J., Gilles C. Immunohistochemical localization of cholecystokinin- and gastrin-like peptides in the brain and hypophysis of the rat. Proc Natl Acad Sci USA 1980, 77:1190-1194.
44. Weiss F., Tanzer D.J., Ettenberg A. Opposite actions of CCK-8 on amphetamine-induced hyperlocomotion and stereotypy following intracerebroventricular and intra-accumbens injections in rats. Pharmacol Biochem Behav 1988, 30:309-317.
45. Riddle E.L., Fleckenstein A.E., Hanson G.R. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J 2006, 8:E413-E418.
46. Hao L.N., Wang M., Zhang X.-D., Yang T. Control of peroxyntrite-induced production of inducible nitric oxide synthase isoforms and antagonism of cholecystokinin octapeptide -8 in retinal pigment epithelial cells in vivo. Int J Ophthalmol 2011, 4:605-610.
47. Madsen-Bouterse S.A., Kowluru R.A. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 2008, 9:315-327.
48. Nicotera P., Bonfoco E., Brune B. Mechanisms for nitric oxide-induced cell death: involvement of apoptosis. Adv Neuroimmunol 1995, 5:411-420.
49. Halpin L.E., Collins S.A., Yamamoto B.K. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci 2014, 97:37-44.
50. Uehara T. Accumulation of misfolded protein through nitrosative stress linked to neurodegenerative disorders. Antioxid Redox Signal 2007, 9:597-601.
51. Mark K.A., Soghomonian J.J., Yamamoto B.K. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci 2004, 24:11449-11456.
52. Thomas D.M., Kuhn D.M. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res 2005, 1050:190-198.
53. de Bock F., Dornand J., Rondouin G. Release of TNF alpha in the rat hippocampus following epileptic seizures and excitotoxic neuronal damage. Neuroreport 1996, 7:1125-1129.
54. Chaparro-Huerta V., Rivera-Cervantes M.C., Flores-Soto M.E., Gómez-Pinedo U., Beas-Zárate C. Proinflammatory cytokines and apoptosis following glutamate-induced excitotoxicity mediated by p38 MAPK in the hippocampus of neonatal rats. J Neuroimmunol 2005, 2005:53-62.
55. Wyeth M.S., Zhang N., Houser C.R. Increased cholecystokinin labeling in the hippocampus of a mouse model of epilepsy maps to spines and glutamatergic terminals. Neuroscience 2012, 202:371-383.
56. Daw M.I., Pelkey Kenneth A., Chittajallu Ramesh, McBain C.J. Presynaptic kainate receptor activation preserves asynchronous GABA release despite the reduction in synchronous release from hippocampal cholecystokinin interneurons. J Neurosci 2010, 30:11202-11209.
57. Miyamoto S., Shikata K., Miyasaka K., Okada S., Sasaki M., Kodera R., et al. Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin. Diabetes 2012, 61:897-907.
58. Cevik-Aras H., Ekstrom J. Anti-inflammatory action of cholecystokinin and melatonin in the rat parotid gland. Oral Dis 2010, 16:661-667.
59. Zhang J.G., Cong B., Li Q.X., Chen H.Y., Qin J., Fu L.H. Cholecystokinin octapeptide regulates lipopolysaccharide-activated B cells co-stimulatory molecule expression and cytokines production in vitro. Immunopharmacol Immunotoxicol 2011, 33:157-163.